Get started
Author

Scarlett Czarnecki

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial
2016 · Steven G. DuBois, Araz Marachelian, et al. · Journal of Clinical Oncology · 133
131I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study
2015 · Gregory A. Yanik, Judith G. Villablanca, et al. · Transplantation and Cellular Therapy · 99
PDF
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma
2016 · Judith G. Villablanca, Samuel L. Volchenboum, et al. · Pediatric Blood & Cancer · 94
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium
2021 · Steven G. DuBois, M. Meaghan Granger, et al. · Journal of Clinical Oncology · 88
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
2018 · Steven G. DuBois, Yael P. Mosse, et al. · Clinical Cancer Research · 87
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium
2013 · Barry J. Maurer, Min H. Kang, et al. · Pediatric Blood & Cancer · 86
Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma
2015 · Steven G. DuBois, Susan Groshen, et al. · Clinical Cancer Research · 71
Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
2017 · Araz Marachelian, Judith G. Villablanca, et al. · Clinical Cancer Research · 59
Fenretinide (4-HPR)/Lym-X-Sorb (LXS) oral powder plus ketoconazole in patients with high-risk (HR) recurrent or resistant neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) Consortium trial.
2014 · Barry James Maurer, Julia Lynne Glade Bender, et al. · Journal of Clinical Oncology · 11
Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study
2014 · Min H Kang, Judith G Villablanca, et al. · BMC Research Notes · 9
PDF
Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.
2020 · Steven G. DuBois, Meaghan Granger, et al. · Journal of Clinical Oncology · 5
A phase I NANT study of lenalidomide with ch14.18 and isotretinoin (RA) in patients with refractory/recurrent neuroblastoma (RR-NB).
2018 · Araz Marachelian, Judith Villablanca, et al. · Journal of Clinical Oncology · 4
Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
2016 · Steven G. DuBois, Araz Marachelian, et al. · Journal of Clinical Oncology · 2
Monitoring plasma voriconazole levels may prevent subtheraputic dosing in pediatric stem cell transplant (SCT) patients
2007 · J. D. Morris, D. Voskoboynik, et al. · Journal of Clinical Oncology · 1
Data from Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma
2023 · Steven G. DuBois, Susan Groshen, et al.
Figure A2 from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
2023 · Araz Marachelian, Judith G. Villablanca, et al.
Figure A3 from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
2023 · Araz Marachelian, Judith G. Villablanca, et al.
Supplementary Figure Legends from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
2023 · Araz Marachelian, Judith G. Villablanca, et al.
Figure A1 from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
2023 · Araz Marachelian, Judith G. Villablanca, et al.
Supplemental Patients, Methods, and Tables from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
2023 · Araz Marachelian, Judith G. Villablanca, et al.
Supplemental Figure 1 from Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma
2023 · Steven G. DuBois, Susan Groshen, et al.
Figure A3 from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
2023 · Araz Marachelian, Judith G. Villablanca, et al.
Supplemental Patients, Methods, and Tables from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
2023 · Araz Marachelian, Judith G. Villablanca, et al.
Figure A1 from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
2023 · Araz Marachelian, Judith G. Villablanca, et al.
Supplemental Figure 2 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
2023 · Steven G. DuBois, Yael P. Mosse, et al.
Works count: 42
Citation count: 749
H-index: 9
I10-index: 9
Year
Topic
Type